Delcath Systems (DCTH) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Delcath Systems (NASDAQ: DCTH):

• 11/19/2025 – Delcath Systems had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Delcath Systems had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Delcath Systems was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 11/5/2025 – Delcath Systems had its price target lowered by analysts at Stephens from $25.00 to $18.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – Delcath Systems had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $23.00 price target on the stock.
• 10/21/2025 – Delcath Systems had its “buy” rating reaffirmed by analysts at Craig Hallum. They now have a $20.00 price target on the stock.
• 10/21/2025 – Delcath Systems had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $21.00 price target on the stock.
• 10/20/2025 – Delcath Systems was given a new $30.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
• 10/12/2025 – Delcath Systems was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/8/2025 – Delcath Systems had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/4/2025 – Delcath Systems was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 9/27/2025 – Delcath Systems had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Delcath Systems

In related news, CEO Gerard J. Michel bought 11,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were bought at an average price of $8.53 per share, with a total value of $98,095.00. Following the completion of the transaction, the chief executive officer directly owned 330,834 shares in the company, valued at approximately $2,822,014.02. This represents a 3.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 17.40% of the stock is currently owned by corporate insiders.

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.